JP2015504443A - 加水分解性脱保護工程及び固相抽出を含む18f−標識化合物の生産 - Google Patents
加水分解性脱保護工程及び固相抽出を含む18f−標識化合物の生産 Download PDFInfo
- Publication number
- JP2015504443A JP2015504443A JP2014543884A JP2014543884A JP2015504443A JP 2015504443 A JP2015504443 A JP 2015504443A JP 2014543884 A JP2014543884 A JP 2014543884A JP 2014543884 A JP2014543884 A JP 2014543884A JP 2015504443 A JP2015504443 A JP 2015504443A
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- labeled compound
- compound
- fmiso
- cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0006—Controlling or regulating processes
- B01J19/004—Multifunctional apparatus for automatic manufacturing of various chemical products
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0093—Microreactors, e.g. miniaturised or microfabricated reactors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00781—Aspects relating to microreactors
- B01J2219/00788—Three-dimensional assemblies, i.e. the reactor comprising a form other than a stack of plates
- B01J2219/00799—Cup-shaped
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00781—Aspects relating to microreactors
- B01J2219/00873—Heat exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00781—Aspects relating to microreactors
- B01J2219/00889—Mixing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00781—Aspects relating to microreactors
- B01J2219/00905—Separation
- B01J2219/00916—Separation by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Manufacturing & Machinery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
(i)保護前駆体化合物を18Fで標識する工程、
(ii)工程(i)で得られた18F−標識化合物を加水分解により脱保護する工程、
(iii)工程(ii)で得られた脱保護18F−標識化合物を水で希釈する工程、
(iv)工程(iii)で得られた希釈された溶液を固相抽出(SPE)カラムに通すことによって、脱保護18F−標識化合物をカラムに捕捉する工程、
(v)工程(iv)で得られた脱保護18F−標識化合物をSPEカラムから溶出する工程
を含む方法を提供する。但し、脱保護工程の後に中和する工程を行わない。
R1はヒドロキシル官能性のための保護基であり、
R2は脱離基である。
(a)脱保護18F−標識化合物に第1の容量の水を加えて第1の希釈溶液を得ること、
(b)第1の希釈溶液のアリコートにその後の容量の水を加えてその後の希釈溶液を得ること
を含む。
(i)本明細書に定義されている保護前駆体化合物を収容する容器、
(ii)本明細書に定義されている適切な18F源と共に保護前駆体化合物を収容する容器を溶出するための手段、
(iii)適切な18F源と共に保護前駆体化合物を収容する容器の溶出後に得られた18F−標識化合物を脱保護するための手段、
(iv)脱保護18F−標識化合物の捕捉に適した、本明細書に定義されているSPEカラム
を含む。但し、脱保護18F−標識化合物の脱保護18F−標識化合物のpHを中和するのに適した中和剤を収容する容器がカセット内に含まれていないし、カセットに流体接続されてもいない。
(iv)過剰の[18F]−フッ化物の除去のためのイオン交換カートリッジ
を含み得る。
実施例1は、本発明の方法に従って18F−FMISOを得る方法を記載する。
EtOH エタノール
18F- フッ化物
18F−FMISO 1−H−1−(3−[18F]フルオロ−2−ヒドロキシプロピル)−2−ニトロイミダゾール
ID 内径
NITTP 1−(2’−ニトロ−1’−イミダゾリル)−2−O−テトラヒドロピラニル−3−O−トルエンスルホニル−プロパンジオール
MeCN アセトニトリル
QMA 第四メチルアンモニウム
THP テトラヒドロピラニル
実施例1: 18 F−FMISOの合成
図1に示したようなカセットをFASTlab合成機(GE Healthcare)に嵌めた。
Claims (11)
- (i)保護前駆体化合物を18Fで標識する工程、
(ii)工程(i)で得られた18F−標識化合物を加水分解によって脱保護する工程、
(iii)工程(ii)で得られた脱保護18F−標識化合物を水で希釈する工程、
(iv)工程(iii)で得られた希釈溶液を固相抽出(SPE)カラムに通すことによって、脱保護18F−標識化合物をカラムに捕捉する工程、
(v)脱保護18F−標識化合物をSPEカラムから溶出する工程
を含んでいるが、脱保護工程の後に中和工程を実施しない、方法。 - 脱保護工程(ii)を酸加水分解によって行う、請求項1記載の方法。
- 18F−標識化合物が、18F−フルオロデオキシグルコース(18F−FDG)、6−[18F]−L−フルオロドーパ(18F−FDOPA)、18F−フルオロチミジン(18F−FLT)、18F−フルオロミソニダゾール(18F−FMISO)、18F−1−(5−フルオロ−5−デオキシ−α−アラビノフラノシル)−2−ニトロイミダゾール(18F−FAZA)、16−α−[18F]−フルオロエストラジオール(18F−FES)、又は6−[18F]−フルオロメタラミノール(18F−FMR)である、請求項1記載の方法。
- 18F−標識化合物が、18F−フルオロデオキシグルコース(18F−FDG)、6−[18F]−L−フルオロドーパ(18F−FDOPA)、18F−フルオロチミジン(18F−FLT)、又は18F−フルオロミソニダゾール(18F−FMISO)である、請求項1記載の方法。
- 18F−標識化合物が18F−フルオロチミジン(18F−FLT)又は18F−フルオロミソニダゾール(18F−FMISO)である、請求項1記載の方法。
- 18F−標識化合物が1−H−1−(3−[18F]フルオロ−2−ヒドロキシプロピル)−2−ニトロイミダゾール(18F−FMISO)である、請求項1記載の方法。
- 保護前駆体化合物が次式Iの化合物である、請求項6記載の方法。
R1はヒドロキシル官能性の保護基であり、
R2は脱離基である。 - 希釈工程が、
(a)脱保護18F−標識化合物に第1の容量の水を加えて第1の希釈溶液を得、
(b)第1の希釈溶液のアリコートにその後の容量の水を加えてその後の希釈溶液を得ることを含む、請求項1乃至請求項7のいずれか1項記載の方法。 - SPEカートリッジがOasis HLB、tC18及びStrata Xから選択される、請求項1乃至請求項8のいずれか1項記載の方法。
- 自動化される、請求項1乃至請求項9のいずれか1項記載の方法。
- 請求項10記載の方法を実施するためのカセットであって、カセットが、
(i)請求項1乃至請求項7のいずれか1項に定義されている保護前駆体化合物を収容する容器、
(ii)保護前駆体化合物を収容する容器を適切な18F源と共に溶出するための手段、
(iii)保護前駆体化合物を収容する容器を適切な18F源と共に溶出した後で得られる18F−標識化合物を脱保護するための手段、
(iv)脱保護18F−標識化合物の捕捉に適した請求項1乃至請求項9のいずれか1項に定義されているSPEカラム
を含んでいるが、脱保護18F−標識化合物のpHを中和するのに適した中和剤を収容する容器が、カセットに含まれておらず、カセットと流体接続してもいない、カセット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564880P | 2011-11-30 | 2011-11-30 | |
US61/564,880 | 2011-11-30 | ||
GB1120586.1 | 2011-11-30 | ||
GB201120586A GB201120586D0 (en) | 2011-11-30 | 2011-11-30 | Solid phase extraction neutralisation |
PCT/EP2012/073926 WO2013079578A1 (en) | 2011-11-30 | 2012-11-29 | Production of 18f- labelled compounds comprising hydrolytic deprotection step and solid phase extraction |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015504443A true JP2015504443A (ja) | 2015-02-12 |
JP6145107B2 JP6145107B2 (ja) | 2017-06-07 |
Family
ID=45508932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014543884A Expired - Fee Related JP6145107B2 (ja) | 2011-11-30 | 2012-11-29 | 加水分解性脱保護工程及び固相抽出を含む18f−標識化合物の生産 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150175553A1 (ja) |
EP (1) | EP2785445A1 (ja) |
JP (1) | JP6145107B2 (ja) |
KR (1) | KR20140097225A (ja) |
CN (1) | CN103958049B (ja) |
AU (1) | AU2012343917A1 (ja) |
BR (1) | BR112014013057A2 (ja) |
CA (1) | CA2856457A1 (ja) |
GB (1) | GB201120586D0 (ja) |
MX (1) | MX2014006548A (ja) |
RU (1) | RU2014118746A (ja) |
WO (1) | WO2013079578A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018235535A1 (ja) * | 2017-06-23 | 2018-12-27 | 日本メジフィジックス株式会社 | 放射性ハロゲン標識化合物の製造方法および放射性医薬の製造方法 |
EP3536686A1 (en) | 2018-03-07 | 2019-09-11 | Nihon Medi-Physics Co., Ltd | Method for producing a radiopharmaceutical composition |
JP2021519756A (ja) * | 2018-03-29 | 2021-08-12 | ジーイー・ヘルスケア・リミテッド | 固相抽出 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3036209B1 (en) * | 2013-08-22 | 2018-08-01 | GE Healthcare Limited | An improved synthesis of [18f]- fluoroalkyl tosylate |
GB201318450D0 (en) * | 2013-10-18 | 2013-12-04 | Ge Healthcare Ltd | Closed evaporation system |
EP3068747A1 (en) * | 2013-11-13 | 2016-09-21 | GE Healthcare Limited | Dual run cassette for the synthesis of 18f-labelled compounds |
GB201411571D0 (en) * | 2014-06-30 | 2014-08-13 | Ge Healthcare Ltd | Radiolabelling method |
GB201420093D0 (en) * | 2014-11-12 | 2014-12-24 | Ge Healthcare Ltd | Pet tracer purification system |
FR3035262B1 (fr) * | 2015-04-16 | 2020-02-07 | P M B | Dispositif de synthese d'un radio-traceur, installation comportant un tel dispositif et procede d'obtention d'un radio-traceur au moyen d'un tel dispositif |
CN108864213B (zh) * | 2018-07-16 | 2021-06-11 | 陕西正泽生物技术有限公司 | 一种柱水解18F-FDG用C18/tC18 SPE柱分离制备18F-FDG的方法 |
WO2020056064A1 (en) | 2018-09-11 | 2020-03-19 | Stanley Satz | Tumor targeted radionuclide therapy and molecular imaging of her2+ cancers and other neoplasms, and precision medicine. |
CN115160167A (zh) * | 2022-08-08 | 2022-10-11 | 江苏华益科技有限公司 | 一种符合gmp规范的18f-fdopa新型制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006133732A1 (en) * | 2005-06-17 | 2006-12-21 | Advanced Accelerator Applications | Process for synthesizing labelled compounds |
JP2008524205A (ja) * | 2004-12-15 | 2008-07-10 | フューチャーケム カンパニー リミテッド | アルコール溶媒中での有機フルオロ化合物の調製方法 |
WO2011044406A2 (en) * | 2009-10-08 | 2011-04-14 | Ge Healthcare Limited | Purification method |
WO2011127345A1 (en) * | 2010-04-08 | 2011-10-13 | Siemens Medical Solutions Usa, Inc. | Synthesis of 18f-labeled tracers in hydrous organic solvents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0229686D0 (en) * | 2002-12-20 | 2003-01-29 | Amersham Plc | Solid-phase fluorination of benzothiazoles |
CN1882590B (zh) * | 2003-09-17 | 2014-03-05 | 詹森药业有限公司 | 作为血清素受体调节剂的稠合杂环化合物 |
-
2011
- 2011-11-30 GB GB201120586A patent/GB201120586D0/en not_active Ceased
-
2012
- 2012-11-20 BR BR112014013057A patent/BR112014013057A2/pt not_active IP Right Cessation
- 2012-11-29 CN CN201280058746.7A patent/CN103958049B/zh not_active Expired - Fee Related
- 2012-11-29 CA CA2856457A patent/CA2856457A1/en not_active Abandoned
- 2012-11-29 KR KR1020147014198A patent/KR20140097225A/ko not_active Application Discontinuation
- 2012-11-29 RU RU2014118746A patent/RU2014118746A/ru unknown
- 2012-11-29 AU AU2012343917A patent/AU2012343917A1/en not_active Abandoned
- 2012-11-29 WO PCT/EP2012/073926 patent/WO2013079578A1/en active Application Filing
- 2012-11-29 US US14/356,766 patent/US20150175553A1/en not_active Abandoned
- 2012-11-29 JP JP2014543884A patent/JP6145107B2/ja not_active Expired - Fee Related
- 2012-11-29 EP EP12794946.9A patent/EP2785445A1/en not_active Withdrawn
- 2012-11-29 MX MX2014006548A patent/MX2014006548A/es unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008524205A (ja) * | 2004-12-15 | 2008-07-10 | フューチャーケム カンパニー リミテッド | アルコール溶媒中での有機フルオロ化合物の調製方法 |
WO2006133732A1 (en) * | 2005-06-17 | 2006-12-21 | Advanced Accelerator Applications | Process for synthesizing labelled compounds |
WO2011044406A2 (en) * | 2009-10-08 | 2011-04-14 | Ge Healthcare Limited | Purification method |
WO2011127345A1 (en) * | 2010-04-08 | 2011-10-13 | Siemens Medical Solutions Usa, Inc. | Synthesis of 18f-labeled tracers in hydrous organic solvents |
Non-Patent Citations (2)
Title |
---|
JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 54, JPN7016001428, 13 July 2011 (2011-07-13), pages 671 - 673, ISSN: 0003333350 * |
MULHOLLAND G KEITH: "SIMPLE RAPID HYDROLYSIS OF ACETYL PROTECTING GROUPS IN THE FDG SYNTHESIS 以下備考", NUCLEAR MEDICINE AND BIOLOGY, vol. V22 N1, JPN5015001754, 1 January 1995 (1995-01-01), US, pages 19 - 23, ISSN: 0003333349 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018235535A1 (ja) * | 2017-06-23 | 2018-12-27 | 日本メジフィジックス株式会社 | 放射性ハロゲン標識化合物の製造方法および放射性医薬の製造方法 |
JPWO2018235535A1 (ja) * | 2017-06-23 | 2020-04-23 | 日本メジフィジックス株式会社 | 放射性ハロゲン標識化合物の製造方法および放射性医薬の製造方法 |
US11318216B2 (en) | 2017-06-23 | 2022-05-03 | Nihon Medi-Physics Co., Ltd. | Method for producing radiohalogen-labeled compound and method for producing radiopharmaceutical |
JP7159157B2 (ja) | 2017-06-23 | 2022-10-24 | 日本メジフィジックス株式会社 | 放射性フッ素標識化合物の製造方法および放射性医薬の製造方法 |
EP3536686A1 (en) | 2018-03-07 | 2019-09-11 | Nihon Medi-Physics Co., Ltd | Method for producing a radiopharmaceutical composition |
JP2019156717A (ja) * | 2018-03-07 | 2019-09-19 | 日本メジフィジックス株式会社 | 放射性医薬組成物の製造方法 |
US10703726B2 (en) | 2018-03-07 | 2020-07-07 | Nihon Medi-Physics Co., Ltd. | Method for producing radiopharmaceutical composition |
JP7100841B2 (ja) | 2018-03-07 | 2022-07-14 | 日本メジフィジックス株式会社 | 放射性医薬組成物の製造方法 |
JP2021519756A (ja) * | 2018-03-29 | 2021-08-12 | ジーイー・ヘルスケア・リミテッド | 固相抽出 |
JP7467353B2 (ja) | 2018-03-29 | 2024-04-15 | ジーイー・ヘルスケア・リミテッド | 固相抽出 |
Also Published As
Publication number | Publication date |
---|---|
WO2013079578A1 (en) | 2013-06-06 |
US20150175553A1 (en) | 2015-06-25 |
BR112014013057A8 (pt) | 2017-06-13 |
KR20140097225A (ko) | 2014-08-06 |
MX2014006548A (es) | 2014-07-09 |
AU2012343917A1 (en) | 2014-06-19 |
CA2856457A1 (en) | 2013-06-06 |
CN103958049A (zh) | 2014-07-30 |
BR112014013057A2 (pt) | 2017-06-13 |
JP6145107B2 (ja) | 2017-06-07 |
CN103958049B (zh) | 2017-04-19 |
RU2014118746A (ru) | 2016-01-27 |
EP2785445A1 (en) | 2014-10-08 |
GB201120586D0 (en) | 2012-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6145107B2 (ja) | 加水分解性脱保護工程及び固相抽出を含む18f−標識化合物の生産 | |
JP6496726B2 (ja) | 18f標識組成物を合成するための二重使用カセット | |
KR101267122B1 (ko) | 2-〔18f〕플루오로-2-데옥시-d-글루코스의 합성을 위한플루오르화 방법 | |
JP6737782B2 (ja) | フッ化物を捕捉する配置 | |
JP6726665B2 (ja) | Petトレーサー精製システム | |
WO2013012817A1 (en) | Methods and compositions for drying in the preparation of radiopharmaceuticals | |
US20230120841A1 (en) | Cassette for stabilised radiolabelling reaction | |
Gu et al. | Labeling strategies with F-18 for positron emission tomography imaging | |
JP7159157B2 (ja) | 放射性フッ素標識化合物の製造方法および放射性医薬の製造方法 | |
Bejot et al. | 18F-Radionuclide chemistry | |
AU2022393769A1 (en) | Method for the preparation of a composition comprising dissolved [18f]fluoride and composition obtainable by the method | |
Karimi et al. | The Role of Recent Development of 18F Radiochemistry in Drug Development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151120 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160512 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170323 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170418 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170512 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6145107 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |